Trial Outcomes & Findings for Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV (NCT NCT01405313)

NCT ID: NCT01405313

Last Updated: 2017-03-20

Results Overview

Physiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep. Apnea-Hypopnea Index is calculated counting all apneas (reduction of respiratory flow by \>90% for at least 10 seconds) plus all hypopneas (reduction of respiratory flow by \>30% for at least 10 seconds with a 4% SpO2 reduction) divided by hours of sleep.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

21 participants

Primary outcome timeframe

One night

Results posted on

2017-03-20

Participant Flow

Clinic population already established on ASV therapy.

All enrolled participants continued through to group assignment.

Participant milestones

Participant milestones
Measure
First Modified ASV Then Conventional ASV
Patients receive Modified ASV algorithm as therapy for 1 night, then Conventional ASV for 1 night
Overall Study
STARTED
21
Overall Study
COMPLETED
21
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Modified ASV/Conventional ASV
n=21 Participants
Therapy used was Modified ASV and then Conventional ASV
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
4 Participants
n=5 Participants
Age, Categorical
>=65 years
17 Participants
n=5 Participants
Age, Continuous
69.9 years
STANDARD_DEVIATION 8.7 • n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
Sex: Female, Male
Male
19 Participants
n=5 Participants
Region of Enrollment
Germany
21 participants
n=5 Participants

PRIMARY outcome

Timeframe: One night

Physiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep. Apnea-Hypopnea Index is calculated counting all apneas (reduction of respiratory flow by \>90% for at least 10 seconds) plus all hypopneas (reduction of respiratory flow by \>30% for at least 10 seconds with a 4% SpO2 reduction) divided by hours of sleep.

Outcome measures

Outcome measures
Measure
Modified ASV AHI
n=21 Participants
1 night of modified ASV therapy with full polysomnography measurements
Conventional ASV AHI
n=21 Participants
1 night of conventional ASV therapy with full polysomnography measurements
Apnea/Hypopnea Index (AHI)
3.9 Events per hour
Standard Deviation 4.7
6.4 Events per hour
Standard Deviation 10.9

SECONDARY outcome

Timeframe: One night

Oxygen desaturation index based on SpO2 measurement of number of dips (number of times per hour of sleep that SpO2 Drops by at least 3% below the basic value) will be recorded, analysed and reported.

Outcome measures

Outcome measures
Measure
Modified ASV AHI
n=21 Participants
1 night of modified ASV therapy with full polysomnography measurements
Conventional ASV AHI
n=21 Participants
1 night of conventional ASV therapy with full polysomnography measurements
Oxygen Desaturation Index (ODI)
5.2 Events per hour
Standard Deviation 5.3
8.2 Events per hour
Standard Deviation 11.8

Adverse Events

Conventional ASV

Serious events: 1 serious events
Other events: 0 other events
Deaths: 0 deaths

Modified ASV

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Conventional ASV
n=21 participants at risk
Intervention was conventional ASV therapy
Modified ASV
n=21 participants at risk
Intervention was modified ASV therapy
Cardiac disorders
Diagnostic Coronary Angiogram
4.8%
1/21 • Number of events 1
0.00%
0/21

Other adverse events

Adverse event data not reported

Additional Information

Director Medical Affairs

ResMed

Phone: +6128841000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place